Cargando…
Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis
BACKGROUND: Hormone receptor positive breast cancer is characterized by the potential for disease recurrence many years after initial diagnosis. Endocrine therapy has been shown to reduce the risk of such recurrence, but the optimal duration of endocrine therapy remains unclear. METHODS: We conducte...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930532/ https://www.ncbi.nlm.nih.gov/pubmed/24586311 http://dx.doi.org/10.1371/journal.pone.0088238 |
_version_ | 1782304541072424960 |
---|---|
author | Al-Mubarak, Mustafa Tibau, Ariadna Templeton, Arnoud J. Cescon, David W. Ocana, Alberto Seruga, Bostjan Amir, Eitan |
author_facet | Al-Mubarak, Mustafa Tibau, Ariadna Templeton, Arnoud J. Cescon, David W. Ocana, Alberto Seruga, Bostjan Amir, Eitan |
author_sort | Al-Mubarak, Mustafa |
collection | PubMed |
description | BACKGROUND: Hormone receptor positive breast cancer is characterized by the potential for disease recurrence many years after initial diagnosis. Endocrine therapy has been shown to reduce the risk of such recurrence, but the optimal duration of endocrine therapy remains unclear. METHODS: We conducted a systematic review and meta-analysis to quantify the benefits and harms of extended adjuvant tamoxifen (>5 years of therapy) compared with adjuvant tamoxifen (5 years of therapy). Odds ratios (ORs) and 95% confidence intervals (CIs) were computed for disease recurrence, death and adverse events. Subgroup analyses by timing of recurrence and baseline lymph node and menopause status were carried. RESULTS: Five trials comprising 21,554 patients were included. Extended adjuvant tamoxifen was not associated with a significant reduction in the risk of recurrence (OR:0.89, 95% CI 0.76–1.05, p = 0.17). There was no association between extended adjuvant tamoxifen and all-cause death (OR:0.99, 95% CI 0.84–1.16, p = 0.88). There was an apparent reduction in risk of recurrence occurring after completion of extended adjuvant tamoxifen with little evidence of effect during therapy, however, this difference was not significant (p for difference 0.10). Subgroup analysis suggested that a greater effect size among lymph node positive patients compared with those who are lymph node negative (NNT: 25 vs. 49). There was no apparent difference in the effect between pre- and post-menopausal patients. Endometrial carcinoma was substantially more frequent with extended adjuvant tamoxifen (OR:2.06, 95% CI 1.65–2.58, p<0.001, number needed to harm:89). CONCLUSION: In unselected patients, extended adjuvant tamoxifen is not associated with a significant reduction in recurrence, or a reduction in all-cause death. Patients with lymph node positive breast cancer may derive some benefit. Reduction in the risk of recurrence appears to occur only after completion of extended adjuvant therapy. |
format | Online Article Text |
id | pubmed-3930532 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-39305322014-02-25 Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis Al-Mubarak, Mustafa Tibau, Ariadna Templeton, Arnoud J. Cescon, David W. Ocana, Alberto Seruga, Bostjan Amir, Eitan PLoS One Research Article BACKGROUND: Hormone receptor positive breast cancer is characterized by the potential for disease recurrence many years after initial diagnosis. Endocrine therapy has been shown to reduce the risk of such recurrence, but the optimal duration of endocrine therapy remains unclear. METHODS: We conducted a systematic review and meta-analysis to quantify the benefits and harms of extended adjuvant tamoxifen (>5 years of therapy) compared with adjuvant tamoxifen (5 years of therapy). Odds ratios (ORs) and 95% confidence intervals (CIs) were computed for disease recurrence, death and adverse events. Subgroup analyses by timing of recurrence and baseline lymph node and menopause status were carried. RESULTS: Five trials comprising 21,554 patients were included. Extended adjuvant tamoxifen was not associated with a significant reduction in the risk of recurrence (OR:0.89, 95% CI 0.76–1.05, p = 0.17). There was no association between extended adjuvant tamoxifen and all-cause death (OR:0.99, 95% CI 0.84–1.16, p = 0.88). There was an apparent reduction in risk of recurrence occurring after completion of extended adjuvant tamoxifen with little evidence of effect during therapy, however, this difference was not significant (p for difference 0.10). Subgroup analysis suggested that a greater effect size among lymph node positive patients compared with those who are lymph node negative (NNT: 25 vs. 49). There was no apparent difference in the effect between pre- and post-menopausal patients. Endometrial carcinoma was substantially more frequent with extended adjuvant tamoxifen (OR:2.06, 95% CI 1.65–2.58, p<0.001, number needed to harm:89). CONCLUSION: In unselected patients, extended adjuvant tamoxifen is not associated with a significant reduction in recurrence, or a reduction in all-cause death. Patients with lymph node positive breast cancer may derive some benefit. Reduction in the risk of recurrence appears to occur only after completion of extended adjuvant therapy. Public Library of Science 2014-02-20 /pmc/articles/PMC3930532/ /pubmed/24586311 http://dx.doi.org/10.1371/journal.pone.0088238 Text en © 2014 Al-Mubarak et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Al-Mubarak, Mustafa Tibau, Ariadna Templeton, Arnoud J. Cescon, David W. Ocana, Alberto Seruga, Bostjan Amir, Eitan Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis |
title | Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis |
title_full | Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis |
title_fullStr | Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis |
title_full_unstemmed | Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis |
title_short | Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis |
title_sort | extended adjuvant tamoxifen for early breast cancer: a meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930532/ https://www.ncbi.nlm.nih.gov/pubmed/24586311 http://dx.doi.org/10.1371/journal.pone.0088238 |
work_keys_str_mv | AT almubarakmustafa extendedadjuvanttamoxifenforearlybreastcancerametaanalysis AT tibauariadna extendedadjuvanttamoxifenforearlybreastcancerametaanalysis AT templetonarnoudj extendedadjuvanttamoxifenforearlybreastcancerametaanalysis AT cescondavidw extendedadjuvanttamoxifenforearlybreastcancerametaanalysis AT ocanaalberto extendedadjuvanttamoxifenforearlybreastcancerametaanalysis AT serugabostjan extendedadjuvanttamoxifenforearlybreastcancerametaanalysis AT amireitan extendedadjuvanttamoxifenforearlybreastcancerametaanalysis |